[go: up one dir, main page]

EP1887013A1 - A process for preparing didanosine - Google Patents

A process for preparing didanosine Download PDF

Info

Publication number
EP1887013A1
EP1887013A1 EP05772872A EP05772872A EP1887013A1 EP 1887013 A1 EP1887013 A1 EP 1887013A1 EP 05772872 A EP05772872 A EP 05772872A EP 05772872 A EP05772872 A EP 05772872A EP 1887013 A1 EP1887013 A1 EP 1887013A1
Authority
EP
European Patent Office
Prior art keywords
water
mixture
compound
salt
dideoxyinosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05772872A
Other languages
German (de)
French (fr)
Inventor
Dingjun Chu
Defa Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SHANGHAI AURISCO INTERNATIONAL TRADING Co Ltd
Original Assignee
SHANGHAI AURISCO INTERNATIONAL TRADING Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SHANGHAI AURISCO INTERNATIONAL TRADING Co Ltd filed Critical SHANGHAI AURISCO INTERNATIONAL TRADING Co Ltd
Publication of EP1887013A1 publication Critical patent/EP1887013A1/en
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the invention relates to a method for the preparation of didanosine.
  • Didanosine is an antiviral drug used to treat human immunodeficiency virus (HIV) infection. It was developed at the National Cancer Institute ( US Pat No.: 4,861,759 ). The chemical name for didanosine is 2',3'-dideoxyinosine (DDI). Didanosine is one of the most important anti-HIV drugs. There are two main synthetic routes to didanosine: 1) catalytic hydrogenation of compound II (below) and removal of protecting group; and 2) removal of protecting group (R) in position 5' from compound II to obtaib 2',3'-didehydro-2',3'-dideoxyinosine ("D4l”), followed by hydrogenated to obtain DDI.
  • D4l obtaib 2',3'-didehydro-2',3'-dideoxyinosine
  • the problem to be solved is to overcome the shortcomings of the methods mentioned above, and to provide a new method for preparing 2',3'-dideoxyinosine (DDI) of a high purity.
  • the invention provides a new method to prepare didanosine of formula I.
  • This new method comprises (a) removing the protecting group in position 5' of the compound II by hydrolysis under basic reaction conditions, and simultaneously enolizing the carbonyl group of the purine ring to yield the stable salt III, i.e. the salt of 2',3'-didehydro-2',3'- dideoxyinosine (X-D4l); (b) producing the salt of 2',3'-dideoxyinosine(X-DDI) through catalytic hydrogenation of X-D4l; and (c) neutralizing X-DDI with acid to obtain compound I, i.e., didanosine.
  • X is a cation, including an organic cation, such as, e.g., an alkali metal ion, an ammonium ion, or a quaternary ammonium cation; preferably, Na + , K + , NH 4 + or CH 3 NH 3 + , and more preferably Na + ;
  • Y is a corresponding anion;
  • R is acyl, acetoxy, alkyl, or silyl, such as, e.g., acetyloxy, 2,5,5-trimethyl-1,3-dioxolane -4-carboxylate, or tert-butyldimethylsilyl.
  • compound IV is obtained by catalytically hydrogenating compound III or its hydrate in a purified form or as crude solution from the previous step.
  • the pH in the range of between 8.5 and 9.5 is preferable for hydrogenation.
  • the catalyst used in hydrogenation is Raney nickel or palladium carbon, and it can be re-used. Then, compound IV is neutralized with acid to yield didanosine of high purity.
  • a suitable solvent should be used and the pH should be maintained at above 8.
  • the solvent can be water, ammonia water, lye, alcohol, alcohol water mixtures, ketone water mixtures, or nitrile water mixtures, etc., such as, e.g., methanol, a mixture of methanol and water, a mixture of ethanol and water, a mixture of isopropanol and water, a mixture of acetonitrile and water, a mixture of acetone and water, ammonia water, or a mixture of methylamine and water, etc.
  • the acid used for neutralization is an inorganic acid or an organic acid, such as, e.g., hydrochloric acid, acetic acid, etc, and preferably acetic acid.
  • the base used in the hydrolysis of compound II to compound III can be an inorganic base, an organic base, or a mixture thereof, as long as the pH of the solution is maintained above 8.5, and preferably the base is a solution of potassium hydroxide, sodium hydroxide, potassium carbonate, sodium carbonate, or methylamine.
  • the other object of the invention is to provide a new key intermediate compound III (X-D4l ⁇ nH 2 O) useful in the synthesis of didanosine.
  • Said compound is a water soluble, stable salt of 2',3'-didehydro-2',3'- dideoxyinosine, the structural formula of which is as follows: wherein X is a cation, such as, e.g., Na + , K + , Mg ++ , Ca ++ , or NH 4 + , and n is between 0 and 3.
  • These salts include salts obtained with organic cations, alkali, alkali metal ions, ammonium ions, or quaternary ammonium cations, and sodium salts are preferable.
  • An alkali metal salt can be obtained by the reaction of an alkali metal with compound II. When the pH of the solution is above 8, the product is very stable. In solid form, the product is a hydrate and the number of water molecules is between
  • Compound II is hydrolyzed in a solution with the pH above 8.5 to yield X-D4l. After adding organic solvent, compound III (X-D4l ⁇ nH 2 O) crystallizes out.
  • the base used in hydrolysis is an inorganic base, an organic base, or a mixture thereof; and preferably potassium hydroxide, sodium hydroxide, potassium carbonate, sodium carbonate, or methylamine.
  • the organic solvent should be water-soluble, e.g., an alcoholic solvent, a ketonic solvent, a nitrilic solvent, etc., such as, e.g., isopropanol, acetone, acetonitrile, or tetrahydrofuran.
  • the method presented herein produces didanosine with high purity, high yield, high quality, and low cost.
  • Fig.1 , 2 , and 3 illustrate NMR spectra of the product obtained in Example 3.
  • NaOH can be replaced by KOH or strong organic base to obtain a corresponding salt of D4l.
  • the filter cake was washed with 100 mL of methanol and dried at a temperature of between 55°C and 60°C. About 60 g of DDI was obtained. If needed, a high purity product can be obtained by recrystallization from methanol.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

This invention provides a method for preparing didanosine. The method comprises removing a protecting group in position 5' of compound II by hydrolysis under basic reaction conditions, and simultaneously enolizing of the carbonyl group of the purine ring to obtain a stable salt, and then producing the salt of 2',3-dideoxyinosine through catalytic hydrogenation, which salt is finally converted with acid to yield the finished product.

Description

  • Field of the Invention
  • The invention relates to a method for the preparation of didanosine.
  • Background of the Invention
  • Didanosine is an antiviral drug used to treat human immunodeficiency virus (HIV) infection. It was developed at the National Cancer Institute ( US Pat No.: 4,861,759 ). The chemical name for didanosine is 2',3'-dideoxyinosine (DDI). Didanosine is one of the most important anti-HIV drugs. There are two main synthetic routes to didanosine: 1) catalytic hydrogenation of compound II (below) and removal of protecting group; and 2) removal of protecting group (R) in position 5' from compound II to obtaib 2',3'-didehydro-2',3'-dideoxyinosine ("D4l"), followed by hydrogenated to obtain DDI.
  • The two methods have the disadvantages of low yield and high cost. However, HIV-infected patients generally require inexpensive treatment, which limits the application of didanosine.
  • Description of the invention:
  • The problem to be solved is to overcome the shortcomings of the methods mentioned above, and to provide a new method for preparing 2',3'-dideoxyinosine (DDI) of a high purity.
  • Thus, the invention provides a new method to prepare didanosine of formula I.
  • This new method comprises (a) removing the protecting group in position 5' of the compound II by hydrolysis under basic reaction conditions, and simultaneously enolizing the carbonyl group of the purine ring to yield the stable salt III, i.e. the salt of 2',3'-didehydro-2',3'- dideoxyinosine (X-D4l); (b) producing the salt of 2',3'-dideoxyinosine(X-DDI) through catalytic hydrogenation of X-D4l; and (c) neutralizing X-DDI with acid to obtain compound I, i.e., didanosine.
  • The method is illustrated as follows:
    Figure imgb0001
    wherein X is a cation, including an organic cation, such as, e.g., an alkali metal ion, an ammonium ion, or a quaternary ammonium cation; preferably, Na+, K+, NH4 + or CH3NH3 +, and more preferably Na+; Y is a corresponding anion; R is acyl, acetoxy, alkyl, or silyl, such as, e.g., acetyloxy, 2,5,5-trimethyl-1,3-dioxolane -4-carboxylate, or tert-butyldimethylsilyl.
  • When pH value is maintained above 8, compound IV is obtained by catalytically hydrogenating compound III or its hydrate in a purified form or as crude solution from the previous step. The pH in the range of between 8.5 and 9.5 is preferable for hydrogenation. The catalyst used in hydrogenation is Raney nickel or palladium carbon, and it can be re-used. Then, compound IV is neutralized with acid to yield didanosine of high purity.
  • When compound III is hydrogenated after purification, a suitable solvent should be used and the pH should be maintained at above 8. The solvent can be water, ammonia water, lye, alcohol, alcohol water mixtures, ketone water mixtures, or nitrile water mixtures, etc., such as, e.g., methanol, a mixture of methanol and water, a mixture of ethanol and water, a mixture of isopropanol and water, a mixture of acetonitrile and water, a mixture of acetone and water, ammonia water, or a mixture of methylamine and water, etc.
  • The acid used for neutralization is an inorganic acid or an organic acid, such as, e.g., hydrochloric acid, acetic acid, etc, and preferably acetic acid.
  • The base used in the hydrolysis of compound II to compound III can be an inorganic base, an organic base, or a mixture thereof, as long as the pH of the solution is maintained above 8.5, and preferably the base is a solution of potassium hydroxide, sodium hydroxide, potassium carbonate, sodium carbonate, or methylamine.
  • The other object of the invention is to provide a new key intermediate compound III (X-D4l·nH2O) useful in the synthesis of didanosine. Said compound is a water soluble, stable salt of 2',3'-didehydro-2',3'- dideoxyinosine, the structural formula of which is as follows:
    Figure imgb0002
    wherein X is a cation, such as, e.g., Na+, K+, Mg++, Ca++, or NH4 +, and n is between 0 and 3. These salts include salts obtained with organic cations, alkali, alkali metal ions, ammonium ions, or quaternary ammonium cations, and sodium salts are preferable. An alkali metal salt can be obtained by the reaction of an alkali metal with compound II. When the pH of the solution is above 8, the product is very stable. In solid form, the product is a hydrate and the number of water molecules is between 0.5 and 3.
  • Compound II is hydrolyzed in a solution with the pH above 8.5 to yield X-D4l. After adding organic solvent, compound III (X-D4l·nH2O) crystallizes out. The base used in hydrolysis is an inorganic base, an organic base, or a mixture thereof; and preferably potassium hydroxide, sodium hydroxide, potassium carbonate, sodium carbonate, or methylamine. The organic solvent should be water-soluble, e.g., an alcoholic solvent, a ketonic solvent, a nitrilic solvent, etc., such as, e.g., isopropanol, acetone, acetonitrile, or tetrahydrofuran.
  • The method presented herein produces didanosine with high purity, high yield, high quality, and low cost.
  • The following examples are intended to show how to practice of invention and are not intended to restrict the scope of thereof.
  • Fig.1, 2, and 3 illustrate NMR spectra of the product obtained in Example 3.
  • Example 1
  • Preparation of DDI from 5'-acetoxy-D4l
  • 20 g of 5'-acetoxy-D4l was dissolved in 200 mL of acetonitrile. The solution was cooled to 5°C. Aqueous NaOH was added dropwise to the reaction mixture while stirring and the pH of the solution was maintained above 8.5. The completion of the protecting group removal was followed by TLC. After deprotection, 70 g of Raney nickel was added and the intermediate was hydrogenated with hydrogen gas at room temperature and normal pressure. The completion of hydrogenation was determined by HPLC. The solution was condensed under reduced pressure, and then neutralized with acetic acid. The crystalline product was filtered and dried. About 14 g of a solid was obtained. The dried DDI was recrystallized from methanol to obtain high purity DDI.
  • Example 2
  • Preparation of DDI from 2',3'-Didehydro-5'-O-(2,5,5-trimethyl-1,3-dioxolan-4-on-2-yl)-2',3'-dideoxyinosine
  • 20 g of 2',3'-Didehydro-5'-O-(2,5,5-trimethyl-1,3-dioxolan-4-on-2-yl)-2',3'-dideoxyinosine was dissolved in 200 mL of acetonitrile. The solution was cooled to 5°C. Aqueous NaOH was slowly added dropwise into the reaction mixture while stirring. The pH of the solution was maintained at above 8.5. The completion of deprotection was followed by TLC. After completion, 50 g of Raney Nickel was added and the intermediate was hydrogenated with hydrogen gas at room temperature and normal pressure. The completion of hydrogenation was followed by HPLC. The solution was condensed under reduced pressure, and then neutralized with acetic acid. The crystallized product was filtered and dried. About 9 g of solid was obtained. The dried DDI was recrystallized with methanol to obtain high purity DDI.
  • Example 3
  • Preparation of Na-D4l·2H2O
    Figure imgb0003
  • 45 mL of 1 N NaOH solution was cooled down to below 10°C. Then 10 g of D4l was added, and the reaction mixture was stirred for 0.5 hours while maintaining the temperature at 10-15°C. The pH of the solution was maintained at between 9.5 and 11. Then, 600 mL of isopropanol was added slowly, and stirred for 2 hours at room temperature until the product crystallized. The mixture was filtered and the crystals were washed with 100 mL of isopropanol, and then dried in vacuum for 24 hours at a temperature of below 50°C. As a result, about 11 g of Na-D4l·2H2O was obtained.
  • Identification tests:
  • (1) NMR: See Figs.1-3.
  • (2) Water (Karl Fischer titration): theoretical value is 12.3% and the test result was 12.4%.
  • In the above methods, NaOH can be replaced by KOH or strong organic base to obtain a corresponding salt of D4l.
  • Example 4
  • Preparation of DDI from purified X-D4l·nH2O
  • 100 g of Na-D4l·2H2O was dissolved in 1000 mL of methanol. The reaction vessel was flushed with nitrogen. 500 g of activated Raney nickel was added. The reaction mixture was placed under an atmosphere of hydrogen gas for 10 hours under normal pressure. The completion of the reaction was followed by HPLC. At the completion of the reaction, the solution was filtered and condensed under reduced pressure to a volume of 100 mL. The condensed solution was then cooled to room temperature, and acetic acid was added dropwise while stirring. The pH was adjusted to between 6.5 and 7 and a white solid crystallized out. The mixture was stirred for 1 hour at room temperature and filtered. The filter cake was washed with 100 mL of methanol and dried at a temperature of between 55°C and 60°C. About 60 g of DDI was obtained. If needed, a high purity product can be obtained by recrystallization from methanol.

Claims (8)

  1. A method of preparing compound I, comprising:
    (a) removing the protecting group in position 5' in compound II by hydrolysis under basic condition, and simultaneously enolizing of the carbonyl group of the purine ring to yield a stable salt of of 2',3'-didehydro-2',3'- dideoxyinosine having formula III,
    (b) producing the salt of 2',3'-dideoxyinosine of formula IV via catalytic hydrogenation, and
    (c) neutralizing the salt of 2',3'-dideoxyinosine of formula IV with acid to obtain didanosine having formula I,
    which is illustrated by the following chemical equations:
    Figure imgb0004
    wherein R is acyl, alkyl or silyl; X is a cation; Y is a corresponding anion; and n is between 0 and 3.
  2. The method of claim 1, wherein X is an alkali metal ion, an ammonium ion, a quaternary ammonium cation, such as, Na+, K+, NH4 + or CH3NH3 +.
  3. The method of claim 1, wherein the solvent used for the preparation of compound IV from compound III through catalytic hydrogenation is selected from water, ammonia water, lye, an alcohol, a mixture of alcohol and water, a mixture of a ketone and water, a mixture of a nitrile and water, etc., e.g., methanol, a mixture of methanol and water, a mixture of ethanol and water, a mixture of isopropanol and water, a mixture of acetonitrile and water, a mixture of acetone and water, ammonia water or a mixture of methylamine and water; the catalyst used in the hydrogenation is Raney nickel or palladium on carbon, and the pH during the catalytic hydrogenation is maintained at between 8 and 14.
  4. The method of claim 1, wherein the acid used for the preparation of compound I from compound IV through neutralization is an inorganic acid or an organic acid, such as, e.g., hydrochloric acid or acetic acid.
  5. The method of claim 1, wherein an intermediate in the synthesis of the compound of formula I is the salt of 2',3'-didehydro-2',3'- dideoxyinosine, which has the structure of formula III, as follows:
    Figure imgb0005
    X is an alkali metal ion, an ammonium ion, or a quaternary ammonium cation, such as, Na+, K+, NH4 + or CH3NH3 +, and n is between 0.5- and 3.
  6. The method of claim 5, wherein said salt of 2',3'-didehydro-2',3'-dideoxyinosine of formula III is obtained by hydrolysis of compound II in a solution having a pH of between 8.5 and 14 or a pH greater than 8.5, followed by crystallization from an organic solvent; and the structural formula of compound II is as follows:
    Figure imgb0006
    R is an acyl, an acetoxy, an alkyl or a silyl, such as acetyloxy, 2,5,5-trimethyl-1,3-dioxolane -4-carboxylate, or tert-butyldimethylsilyl.
  7. The method of claims 1 or 4, wherein the new compound of formula III or its hydrate can be used in subsequent steps after purification or without purification in a crude form.
  8. The method of claim 5, wherein the base used in the hydrolysis for the preparation of salt of 2',3'-didehydro-2',3'- dideoxyinosine is an inorganic base, an organic base, or a mixture thereof, such as, e.g., potassium hydroxide, sodium hydroxide, potassium carbonate, sodium carbonate, or methylamine, or a mixture thereof; said organic solvent is an alcoholic solvent, a ketonic solvent, or a nitrilic solvent, such as isopropanol, acetone, acetonitrile, or tetrahydrofuran.
EP05772872A 2005-05-30 2005-07-18 A process for preparing didanosine Withdrawn EP1887013A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNB2005100262912A CN100537588C (en) 2005-05-30 2005-05-30 A kind of synthetic method of didanosine
PCT/CN2005/001059 WO2006128328A1 (en) 2005-05-30 2005-07-18 A process for preparing didanosine

Publications (1)

Publication Number Publication Date
EP1887013A1 true EP1887013A1 (en) 2008-02-13

Family

ID=37481209

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05772872A Withdrawn EP1887013A1 (en) 2005-05-30 2005-07-18 A process for preparing didanosine

Country Status (3)

Country Link
EP (1) EP1887013A1 (en)
CN (1) CN100537588C (en)
WO (1) WO2006128328A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7750153B2 (en) * 2005-07-05 2010-07-06 Hetero Drugs Limited Process for the preparation of didanosine using novel intermediates

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104211746B (en) * 2014-09-11 2016-08-31 天方药业有限公司 A kind of synthetic method of didanosine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455339A (en) * 1986-05-01 1995-10-03 University Of Georgia Research Foundation, Inc. Method for the preparation of 2',3'-dideoxy and 2',3'-dideoxydide-hydro nucleosides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006128328A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7750153B2 (en) * 2005-07-05 2010-07-06 Hetero Drugs Limited Process for the preparation of didanosine using novel intermediates

Also Published As

Publication number Publication date
WO2006128328A1 (en) 2006-12-07
CN1872868A (en) 2006-12-06
CN100537588C (en) 2009-09-09

Similar Documents

Publication Publication Date Title
CA1239639A (en) Epimeric azahomoerythromycin a derivative and intermediates therefor
PT102006B (en) NEW AZITROMYCIN PREPARATION PROCESS
HU199864B (en) Process for production of derivatives of macrolide
WO2013008247A1 (en) Process for preparation of (dl) -norepinephrine acid addition salt, a key intermediate of (r) - (-) - norepinephrine
JPS6241502B2 (en)
EP0024210B1 (en) Process for the production of optically active threo-3-(3,4-dihydroxyphenyl) serine, and product thus produced
IE911536A1 (en) Process for the preparation of¹1,5-(alkylimino)-1,5-dideoxy-d-glucitol and derivatives¹thereof
EP1887013A1 (en) A process for preparing didanosine
HU221793B1 (en) Process for the preparation of ropivacaine hydrochloride monohydrate
US7696356B2 (en) Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-methylene-4H-carbazol-4-one and ondansetron therefrom
DK170331B1 (en) Process for the preparation of rimantadine
US3595853A (en) Ribofuranosyl cytosine and arabinofuranosyl cytosine derivatives
EP1709057B1 (en) Synthesis of spongosine
US2384105A (en) Ribitylaminobenzenes and process for the manufacture thereof
CN1035005C (en) A new method for preparing 6-(3-dimethylaminopropionyl)forskolin
CN101155820A (en) Preparation method of 6,7,8-trihydroxy-1-hydroxymethyl-3-oxo-2-oxa-4-azabicyclo[3.3.1]nonane
RU2144924C1 (en) Method of preparing azitromicyn and methods for production of intermediates
EP3031800B1 (en) Process for the preparation of high purity miglustat
CN113549072B (en) A preparation method of tofacitinib impurity I
JP5192807B2 (en) Stable crystals of protected pseudouridine
US20080293938A1 (en) Novel Process for the Preparation of Didanosine Using Novel Intermediates
WO2007064663A2 (en) Process for the preparation of 1-(aminomethyl)cyclohexaneacetic acid
JPH09249681A (en) 6-0-(2-acetamidoethylphosphonyl)-d-mannopyranoside derivative and its production
KR20090010546A (en) Method for preparing gabapentin and intermediates
JPS633877B2 (en)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071027

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120201